US 11364300
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
granted A61KA61K31/436A61K31/519
Quick answer
US patent 11364300 (C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors) held by Revolution Medicines, Inc. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/436, A61K31/519, A61K31/553, A61K47/545